Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAHOGANY: zanubrutinib plus anti-CD20 antibodies versus lenalidomide plus rituximab in relapsed/refractory follicular or marginal zone lymphoma
2022-502548-12-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (3 arms), sponsored by BeOne Medicines. Primary endpoints: Progression-free survival in relapsed/refractory follicular lymphoma cohort and Progression-free survival in relapsed/refractory marginal zone lymphoma cohort. Planned start Sep 2023; status: authorised.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2022-502548-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502548-12-00.